Impact of skeletal muscle volume on patients with <scp>BCLC stage‐B</scp> hepatocellular carcinoma undergoing sorafenib therapy
-
- Issei Saeki
- Department of Gastroenterology and Hepatology Yamaguchi University Graduate School of Medicine Yamaguchi Japan
-
- Takahiro Yamasaki
- Department of Oncology and Laboratory Yamaguchi University Graduate School of Medicine Yamaguchi Japan
-
- Yurika Yamauchi
- Department of Gastroenterology and Hepatology Yamaguchi University Graduate School of Medicine Yamaguchi Japan
-
- Tomokazu Kawaoka
- Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
-
- Shinsuke Uchikawa
- Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
-
- Akira Hiramatsu
- Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
-
- Hiroshi Aikata
- Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
-
- Kazufumi Kobayashi
- Department of Gastroenterology, Graduate School of Medicine Chiba University Chiba Japan
-
- Takayuki Kondo
- Department of Gastroenterology, Graduate School of Medicine Chiba University Chiba Japan
-
- Sadahisa Ogasawara
- Department of Gastroenterology, Graduate School of Medicine Chiba University Chiba Japan
-
- Tetsuhiro Chiba
- Department of Gastroenterology, Graduate School of Medicine Chiba University Chiba Japan
-
- Reo Kawano
- National Center for Geriatrics and Gerontology Innovation Center for Translational Research Aichi Japan
-
- Kazuaki Chayama
- Collaborative Research Laboratory of Medical Innovation, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan
-
- Naoya Kato
- Department of Gastroenterology, Graduate School of Medicine Chiba University Chiba Japan
-
- Taro Takami
- Department of Gastroenterology and Hepatology Yamaguchi University Graduate School of Medicine Yamaguchi Japan
Abstract
<jats:title>Abstract</jats:title><jats:sec><jats:title>Aim</jats:title><jats:p>Skeletal muscle volume has been reported to be an important factor that determines overall survival (OS) and post‐progression survival (PPS) in patients with hepatocellular carcinoma (HCC). However, the impact of skeletal muscle volume on HCC with Barcelona Clinic Liver Cancer (BCLC) stage B (BCLC‐B) remains unclear. We conducted sub‐analyses of a previous study on BCLC‐B and compared our findings with data on HCC with BCLC stage C (BCLC‐C).</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We retrospectively enrolled 356 patients with HCC (BCLC‐B, <jats:italic>n</jats:italic> = 78; and BCLC‐C, <jats:italic>n</jats:italic> = 278) undergoing sorafenib therapy. Prognostic factors were analyzed using various parameters, including skeletal muscle volume. Muscle volume (MV) depletion was designated as less than the median value of the skeletal muscle index for each gender (cutoff value: 45.0 cm<jats:sup>2</jats:sup>/m<jats:sup>2</jats:sup> for male and 38.0 cm<jats:sup>2</jats:sup>/m<jats:sup>2</jats:sup> for female participants).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Both OS and PPS showed no significant differences in patients with non‐MV depletion and those with MV depletion in the BCLC‐B group (Median OS [MST] 19.3 vs. 13.5 months [<jats:italic>p</jats:italic> = 0.348]; median PPS 9.7 vs. 10.8 months [<jats:italic>p</jats:italic> = 0.578]). In the BCLC‐C group, patients with non‐MV depletion had a significantly longer OS and PPS compared to patients with MV depletion (MST 12.4 vs. 9.0 months [<jats:italic>p</jats:italic> = 0.001] and median PPS 7.9 vs. 5.4 months [<jats:italic>p</jats:italic> = 0.002]). Multivariate analysis revealed that MV depletion was an independent prognostic factor of OS and PPS in the BCLC‐C group but not in the BCLC‐B group.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Skeletal muscle volume showed little impact on the clinical outcomes of patients with BCLC‐B undergoing sorafenib therapy.</jats:p></jats:sec>
Journal
-
- Cancer Medicine
-
Cancer Medicine 12 (9), 10625-10635, 2023-03-23
Wiley
- Tweet
Details 詳細情報について
-
- CRID
- 1360580232147388928
-
- ISSN
- 20457634
-
- Data Source
-
- Crossref
- KAKEN